Endothelin‐1 in the pathophysiology of obesity and insulin resistance
| Autor: | Joshua S. Speed, Osvaldo Rivera-Gonzalez, Haley N. Jenkins, Yann Gibert |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Adipose tissue 030209 endocrinology & metabolism Endogeny Article Pathogenesis 03 medical and health sciences 0302 clinical medicine Insulin resistance Internal medicine medicine Humans Obesity 030212 general & internal medicine Receptor Endothelin-1 business.industry Public Health Environmental and Occupational Health Receptor Endothelin A medicine.disease Endothelin 1 Pathophysiology Endocrinology Insulin Resistance business |
| Zdroj: | Obes Rev |
| ISSN: | 1467-789X 1467-7881 |
| DOI: | 10.1111/obr.13086 |
| Popis: | The association between plasma endothelin-1 (ET-1) and obesity has been documented for decades, yet the contribution of ET-1 to risk factors associated with obesity are not fully understood. In 1994, one of first papers to document this association also noted a positive correlation between plasma insulin and ET-1, suggesting a potential contribution of ET-1 to the development of insulin resistance. Both endogenous receptors for ET-1, ET(A) and ET(B), are present in all insulin sensitive tissues including adipose, liver, and muscle, and ET-1 actions within these tissues suggest that ET-1 may be playing a role in the pathogenesis of insulin resistance. Further, antagonists for ET-1 receptors are clinically approved making these sites attractive therapeutic targets. This review focuses on known mechanisms through which ET-1 affects plasma lipid profiles and insulin signaling in these metabolically important tissues and also identifies gaps in our understanding of ET-1 in obesity related pathophysiology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text